关注
Chloe Orkin
Chloe Orkin
Professor of Infection and Inequities , Queen Mary University of London
在 qmul.ac.uk 的电子邮件经过验证
标题
引用次数
引用次数
年份
Monkeypox virus infection in humans across 16 countries—April–June 2022
JP Thornhill, S Barkati, S Walmsley, J Rockstroh, A Antinori, LB Harrison, ...
New England Journal of Medicine 387 (8), 679-691, 2022
16882022
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy
MT May, M Gompels, V Delpech, K Porter, C Orkin, S Kegg, P Hay, ...
Aids 28 (8), 1193-1202, 2014
7182014
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti, C Orkin, M Bloch, ...
The Lancet 381 (9868), 735-743, 2013
6532013
Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials
PE Sax, KM Erlandson, JE Lake, GA Mccomsey, C Orkin, S Esser, ...
Clinical Infectious Diseases 71 (6), 1379-1389, 2020
6072020
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
D Corti, JPM Langedijk, A Hinz, MS Seaman, F Vanzetta, ...
PloS one 5 (1), e8805, 2010
5232010
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study
HJ Stellbrink, C Orkin, JR Arribas, J Compston, J Gerstoft, ...
Clinical Infectious Diseases 51 (8), 963-972, 2010
4832010
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
M May, M Gompels, V Delpech, K Porter, F Post, M Johnson, D Dunn, ...
Bmj 343, 2011
4792011
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow …
Writing Group, I Williams, D Churchill, J Anderson, M Boffito, M Bower, ...
HIV medicine 15, 1-6, 2014
4192014
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label …
JK Rockstroh, M Nelson, C Katlama, J Lalezari, J Mallolas, M Bloch, ...
The lancet HIV 2 (8), e319-e327, 2015
4092015
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 …
P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...
The Lancet 393 (10167), 143-155, 2019
4062019
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind …
J Gallant, A Lazzarin, A Mills, C Orkin, D Podzamczer, P Tebas, PM Girard, ...
The Lancet 390 (10107), 2063-2072, 2017
3782017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active …
A Mills, JR Arribas, J Andrade-Villanueva, G DiPerri, J Van Lunzen, ...
The Lancet Infectious Diseases 16 (1), 43-52, 2016
3682016
Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection
C Orkin, K Arasteh, M Górgolas Hernández-Mora, V Pokrovsky, ...
New England Journal of Medicine 382 (12), 1124-1135, 2020
3532020
Monkeypox
O Mitjà, D Ogoina, BK Titanji, C Galvan, JJ Muyembe, M Marks, CM Orkin
The Lancet 401 (10370), 60-74, 2023
2522023
Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naive patients in the ARTEMIS trial
C Orkin, E DeJesus, H Khanlou, A Stoehr, K Supparatpinyo, ...
HIV medicine 14 (1), 49-59, 2013
2492013
Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study
EM Berkowitz, G Moyle, HJ Stellbrink, D Schürmann, S Kegg, M Stoll, ...
The Journal of infectious diseases 211 (8), 1279-1287, 2015
2402015
Mpox in people with advanced HIV infection: a global case series
O Mitjà, A Alemany, M Marks, JIL Mora, JC Rodríguez-Aldama, MST Silva, ...
The Lancet 401 (10380), 939-949, 2023
2372023
British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011
D Asboe, C Aitken, M Boffito, C Booth, P Cane, A Fakoya, AM Geretti, ...
HIV med 13 (1), 1-44, 2012
2362012
Brief communication: rituximab in HIV-associated multicentric Castleman disease
M Bower, T Powles, S Williams, TN Davis, M Atkins, S Montoto, C Orkin, ...
Annals of internal medicine 147 (12), 836-839, 2007
2342007
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
JM Molina, C Orkin, DM Iser, FX Zamora, M Nelson, C Stephan, ...
The Lancet 385 (9973), 1098-1106, 2015
2262015
系统目前无法执行此操作,请稍后再试。
文章 1–20